- By Jessica Profato, MS, CGC
- Posted October 16, 2017
Identifying Patients with Lynch Syndrome: A Paired Somatic/Germline Testing Approach
Lynch syndrome is one of the most common hereditary cancer syndromes, affecting about 1/279-1/440 people in the U.S. It is caused by a genetic mutation in one of five genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. Individuals with Lynch syndrome have a significantly increased lifetime risk for multiple types of cancer including colorectal…
- By Aaron Schmidt
- Posted October 13, 2017
Ambry’s NSGC Research Paves the Way for Future Scientific Discovery, Clinical Practice Enhancements
In our quest to understand all human disease, Ambry employs a team of researchers who investigate topics from every area of genetics research. Throughout her tenure at Ambry, Zoe Powis, MS CGC, Supervisor of Clinical Genomics Research, has contributed much to the broader body of knowledge about the field of genetics. At this year’s National…
- By Aaron Schmidt
- Posted October 9, 2017
Ambry's Research at the National Society of Genetic Counselors 2017 Annual Meeting
We present impactful research to move the science of genetics forward at tradeshow and conferences throughout the year. Check out some of the research, separated by category below, that we brought to this year’s National Society of Genetic Counselor’s annual meeting. Read about the contributions from our lead researcher Zoe Powis and the Ambry…
- By Laura Panos Smith
- Posted October 4, 2017
Hereditary Cancer Tests: Is Bigger Always Better?
Just five short years ago, hereditary cancer testing was much simpler for patients and healthcare providers. There were finite criteria, associated with a handful of genetic conditions, and healthcare providers could order single-gene (or single-syndrome) genetic testing for patients who met those criteria. Since 2012, the field of genetics has…
- By James L. Wilder, MD
- Posted September 11, 2017
The Benefits of Genetic Testing for Your GYN/ONC Practice
An estimated 22,440 women will be diagnosed with ovarian cancer in 2017. Early detection is critical for successful treatment of this disease, which has a 5-year survival rate of 92.5% for women who are diagnosed with early stage/localized ovarian cancer.1 We hope that Ovarian Cancer Awareness Month will bring more women to their healthcare providers…
- By Brian Helfand, MD, PhD
- Posted September 7, 2017
How Genetic Testing Can Benefit Your Urology Practice
An estimated 161,360 men will be diagnosed with prostate cancer in 2017; early detection is critical for successful treatment of this disease. We hope that Prostate Cancer Awareness Month will bring more men to their healthcare providers asking about prostate cancer screening or about their risk of developing this disease. Genetic testing for…
- By Taylor Leigh
- Posted August 29, 2017
Ambry's Agenda for an Influential NSGC 2017
August is quickly wrapping up and all of us at Ambry are preparing for the 36th Annual National Society of Genetic Counselors (NSGC) Conference. We are excited to present new research, participate in panels, and display posters – all focused on the importance of evidence-based, quality genetic testing. The Annual NSGC Conference serves as a…
- By Taylor Leigh
- Posted August 15, 2017
Ambry Advances Understanding of Human Disease Through Epilepsy Gene Research
At Ambry, we believe working together is better, that sharing data is essential to finding answers faster. Our scientists embody these beliefs by collaborating with other talented researchers and physicians to understand human disease, most recently in epilepsy genetics. We are proud to have contributed to the clinical research reviewed…
- By Taylor Leigh
- Posted July 27, 2017
Ambry GC Melissa Truelson Advances Qualified Genetic Counseling in Minnesota
*Editor’s Note: For this article, we interviewed one of Ambry’s genetic counselors, Melissa Truelson, MS, CGC, who was instrumental in passing local healthcare legislation in her home state of Minnesota. One of Ambry’s genetic counselors, Melissa Truelson, MS, CGC, continually strives to advance qualified genetic counseling in…
- By Jessica Profato, MS, CGC
- Posted July 26, 2017
Why Paired Tumor/Germline Testing?
Germline genetic testing is used by many labs to evaluate a patient’s predisposition to hereditary cancer, and produces excellent results in its analysis of many genetic conditions. However, when germline testing is combined with tumor testing as a single paired test, it may yield even more helpful results in certain situations. Specifically,…